XTL Net Income From Continuing Ops vs Reconciled Depreciation Analysis

XTLB Stock

USD 1.85 0.03 1.60%

XTL Biopharmaceutica financial indicator trend analysis is more than just analyzing XTL Biopharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether XTL Biopharmaceuticals is a good investment. Please check the relationship between XTL Biopharmaceutica Net Income From Continuing Ops and its Reconciled Depreciation accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Net Income From Continuing Ops vs Reconciled Depreciation

Net Income From Continuing Ops vs Reconciled Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of XTL Biopharmaceuticals Net Income From Continuing Ops account and Reconciled Depreciation. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between XTL Biopharmaceutica's Net Income From Continuing Ops and Reconciled Depreciation is -0.2. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Reconciled Depreciation in the same time period over historical financial statements of XTL Biopharmaceuticals Ltd, assuming nothing else is changed. The correlation between historical values of XTL Biopharmaceutica's Net Income From Continuing Ops and Reconciled Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of XTL Biopharmaceuticals Ltd are associated (or correlated) with its Reconciled Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Reconciled Depreciation has no effect on the direction of Net Income From Continuing Ops i.e., XTL Biopharmaceutica's Net Income From Continuing Ops and Reconciled Depreciation go up and down completely randomly.

Correlation Coefficient

-0.2

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Net Income From Continuing Ops

Reconciled Depreciation

Most indicators from XTL Biopharmaceutica's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into XTL Biopharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

At present, XTL Biopharmaceutica's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 3.9 M, whereas Selling General Administrative is forecasted to decline to about 697.3 K.

XTL Biopharmaceutica fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Other Current Liab	Total Current Liabilities	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Intangible Assets
Total Assets		1.0	-0.21	-0.98	0.74	0.84	0.87	-0.1	0.99	-0.42	0.98	0.97	0.43	0.15	0.05	0.94	0.86	-0.58	0.97	0.23	0.21	0.98	0.95	-0.57	0.99	-0.06
Total Stockholder Equity	1.0		-0.19	-0.98	0.69	0.81	0.85	-0.08	0.99	-0.43	0.97	0.96	0.43	0.1	0.06	0.94	0.86	-0.56	0.97	0.21	0.25	0.99	0.95	-0.55	0.99	-0.12
Common Stock Shares Outstanding	-0.21	-0.19		0.24	-0.3	-0.21	-0.25	-0.05	-0.13	0.4	-0.27	-0.17	-0.42	-0.25	-0.03	-0.26	-0.2	0.51	-0.19	-0.22	-0.24	-0.11	-0.28	0.54	-0.13	-0.19
Other Stockholder Equity	-0.98	-0.98	0.24		-0.72	-0.8	-0.84	0.07	-0.98	0.36	-0.97	-0.96	-0.36	-0.12	-0.14	-0.9	-0.85	0.6	-0.95	-0.25	-0.23	-0.98	-0.91	0.59	-0.98	0.15
Total Liab	0.74	0.69	-0.3	-0.72		0.69	0.73	0.01	0.71	-0.28	0.72	0.72	0.29	0.29	-0.03	0.67	0.64	-0.49	0.7	0.5	-0.14	0.69	0.68	-0.49	0.71	0.14
Other Current Liab	0.84	0.81	-0.21	-0.8	0.69		0.89	0.02	0.82	-0.22	0.84	0.83	0.22	0.46	-0.08	0.68	0.61	-0.67	0.74	0.1	0.15	0.8	0.71	-0.65	0.82	0.3
Total Current Liabilities	0.87	0.85	-0.25	-0.84	0.73	0.89		-0.25	0.87	-0.15	0.91	0.93	0.16	0.57	0.07	0.68	0.87	-0.81	0.74	0.03	0.06	0.83	0.71	-0.79	0.87	0.36
Other Liab	-0.1	-0.08	-0.05	0.07	0.01	0.02	-0.25		-0.08	-0.28	-0.13	-0.2	0.28	-0.5	-0.38	0.0	-0.35	0.08	-0.07	0.44	0.3	-0.04	0.0	0.06	-0.08	-0.28
Property Plant And Equipment Net	0.99	0.99	-0.13	-0.98	0.71	0.82	0.87	-0.08		-0.33	0.98	0.98	0.33	0.13	0.1	0.89	0.87	-0.6	0.94	0.19	0.22	1.0	0.9	-0.58	1.0	-0.11
Net Debt	-0.42	-0.43	0.4	0.36	-0.28	-0.22	-0.15	-0.28	-0.33		-0.31	-0.22	-1.0	0.36	0.55	-0.66	-0.28	0.01	-0.49	-0.4	-0.42	-0.36	-0.65	0.04	-0.33	0.13
Retained Earnings	0.98	0.97	-0.27	-0.97	0.72	0.84	0.91	-0.13	0.98	-0.31		0.99	0.31	0.26	0.18	0.86	0.89	-0.71	0.91	0.16	0.18	0.96	0.88	-0.7	0.98	-0.02
Accounts Payable	0.97	0.96	-0.17	-0.96	0.72	0.83	0.93	-0.2	0.98	-0.22	0.99		0.22	0.31	0.21	0.82	0.91	-0.7	0.89	0.13	0.14	0.96	0.84	-0.68	0.98	0.01
Cash	0.43	0.43	-0.42	-0.36	0.29	0.22	0.16	0.28	0.33	-1.0	0.31	0.22		-0.36	-0.54	0.66	0.28	-0.02	0.49	0.4	0.42	0.36	0.65	-0.06	0.33	-0.13
Non Current Assets Total	0.15	0.1	-0.25	-0.12	0.29	0.46	0.57	-0.5	0.13	0.36	0.26	0.31	-0.36		0.22	-0.1	0.28	-0.59	-0.02	-0.25	-0.31	0.05	-0.07	-0.59	0.13	0.81
Non Currrent Assets Other	0.05	0.06	-0.03	-0.14	-0.03	-0.08	0.07	-0.38	0.1	0.55	0.18	0.21	-0.54	0.22		-0.1	0.13	-0.21	0.03	-0.03	-0.35	0.09	-0.11	-0.2	0.1	-0.33
Cash And Short Term Investments	0.94	0.94	-0.26	-0.9	0.67	0.68	0.68	0.0	0.89	-0.66	0.86	0.82	0.66	-0.1	-0.1		0.75	-0.35	0.98	0.37	0.28	0.91	1.0	-0.35	0.89	-0.22
Net Receivables	0.86	0.86	-0.2	-0.85	0.64	0.61	0.87	-0.35	0.87	-0.28	0.89	0.91	0.28	0.28	0.13	0.75		-0.65	0.79	0.1	0.12	0.84	0.77	-0.63	0.87	0.08
Common Stock Total Equity	-0.58	-0.56	0.51	0.6	-0.49	-0.67	-0.81	0.08	-0.6	0.01	-0.71	-0.7	-0.02	-0.59	-0.21	-0.35	-0.65		-0.41	0.15	-0.25	-0.55	-0.39	1.0	-0.6	-0.36
Short Term Investments	0.97	0.97	-0.19	-0.95	0.7	0.74	0.74	-0.07	0.94	-0.49	0.91	0.89	0.49	-0.02	0.03	0.98	0.79	-0.41		0.32	0.21	0.95	0.98	-0.4	0.94	-0.22
Non Current Liabilities Total	0.23	0.21	-0.22	-0.25	0.5	0.1	0.03	0.44	0.19	-0.4	0.16	0.13	0.4	-0.25	-0.03	0.37	0.1	0.15	0.32		-0.18	0.21	0.35	0.12	0.19	-0.27
Other Current Assets	0.21	0.25	-0.24	-0.23	-0.14	0.15	0.06	0.3	0.22	-0.42	0.18	0.14	0.42	-0.31	-0.35	0.28	0.12	-0.25	0.21	-0.18		0.24	0.28	-0.25	0.22	-0.19
Property Plant And Equipment Gross	0.98	0.99	-0.11	-0.98	0.69	0.8	0.83	-0.04	1.0	-0.36	0.96	0.96	0.36	0.05	0.09	0.91	0.84	-0.55	0.95	0.21	0.24		0.92	-0.53	1.0	-0.19
Total Current Assets	0.95	0.95	-0.28	-0.91	0.68	0.71	0.71	0.0	0.9	-0.65	0.88	0.84	0.65	-0.07	-0.11	1.0	0.77	-0.39	0.98	0.35	0.28	0.92		-0.39	0.9	-0.18
Common Stock	-0.57	-0.55	0.54	0.59	-0.49	-0.65	-0.79	0.06	-0.58	0.04	-0.7	-0.68	-0.06	-0.59	-0.2	-0.35	-0.63	1.0	-0.4	0.12	-0.25	-0.53	-0.39		-0.58	-0.36
Property Plant Equipment	0.99	0.99	-0.13	-0.98	0.71	0.82	0.87	-0.08	1.0	-0.33	0.98	0.98	0.33	0.13	0.1	0.89	0.87	-0.6	0.94	0.19	0.22	1.0	0.9	-0.58		-0.11
Intangible Assets	-0.06	-0.12	-0.19	0.15	0.14	0.3	0.36	-0.28	-0.11	0.13	-0.02	0.01	-0.13	0.81	-0.33	-0.22	0.08	-0.36	-0.22	-0.27	-0.19	-0.19	-0.18	-0.36	-0.11

Click cells to compare fundamentals

XTL Biopharmaceutica Account Relationship Matchups

XTL Biopharmaceutica fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	7.2M	6.5M	6.6M	4.2M	2.4M	2.3M
Total Stockholder Equity	7.0M	6.2M	5.3M	4.0M	2.2M	2.1M
Liabilities And Stockholders Equity	7.2M	6.5M	6.6M	4.2M	2.4M	2.3M
Total Liab	232K	254K	1.3M	187K	206K	195.7K
Other Current Liab	231K	252K	229K	185K	205K	194.8K
Total Current Liabilities	232K	254K	231K	187K	206K	195.7K
Other Liab	1.0M	465K	2.6M	1.1M	1.2M	1.3M
Net Debt	(4.5M)	(3.6M)	(3.0M)	(2.1M)	(1.4M)	(1.5M)
Retained Earnings	(153.9M)	(154.7M)	(155.1M)	(156.5M)	(158.2M)	(166.2M)
Cash	4.5M	3.6M	3.0M	2.1M	1.4M	1.3M
Cash And Short Term Investments	6.7M	6.0M	6.1M	3.7M	2.0M	1.9M
Short Term Investments	2.3M	2.4M	3.2M	1.6M	605K	574.8K
Non Current Liabilities Total	2.7M	0.0	1K	2.6M	1.1M	2K
Other Current Assets	102K	79K	110K	85K	40K	68K
Total Current Assets	6.8M	6.1M	6.2M	3.8M	2.0M	1.9M
Net Tangible Assets	6.6M	3.2M	5.0M	3.6M	4.2M	4.6M
Net Invested Capital	7.0M	6.2M	5.3M	4.0M	2.2M	4.2M
Net Working Capital	6.6M	5.9M	6.0M	3.6M	1.8M	1.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:

How To Invest In XTL

Details

Is XTL Stock a good investment?

Details

What is XTL Biopharmaceutica's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.76)

Earnings Share

(0.03)

Return On Assets

(0.14)

Return On Equity

(0.13)

The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

XTL Net Income From Continuing Ops vs Reconciled Depreciation Analysis

Net Income From Continuing Ops vs Reconciled Depreciation

Net Income From Continuing Ops vs Reconciled Depreciation Correlation Analysis

Correlation Coefficient

Net Income From Continuing Ops

Reconciled Depreciation

XTL Biopharmaceutica fundamental ratios Correlations

XTL Biopharmaceutica Account Relationship Matchups

High Positive Relationship

High Negative Relationship

XTL Biopharmaceutica fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Property Plant Equipment	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Property Plant Equipment	+ 1.0	Property Plant And Equipment Gross

Cash	- 1.0	Net Debt
Property Plant Equipment	- 0.98	Other Stockholder Equity
Property Plant And Equipment Gross	- 0.98	Other Stockholder Equity
Property Plant And Equipment Net	- 0.98	Other Stockholder Equity
Other Stockholder Equity	- 0.98	Total Stockholder Equity
Other Stockholder Equity	- 0.98	Total Assets